Report

Termination of coverage

Edison Investment Research is terminating coverage on C4X Discovery Holdings (C4XD). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Underlying
C4X Discovery Holdings

C4X Discovery Holdings is a drug discovery company. Co. operates one segment, being the provision of new technologies to improve the drug discovery process for small molecule therapies. Co.'s proprietary target discovery technology Taxonomy3® is used to analyze genetic datasets. It identifies and characterizes defined patient groups and is able to identify previously unknown genetic linkages and interactions between genes and biological pathways in a range of diseases. Co.'s drug design technology also comprises both Conformetrix and MolPlex. These technologies enable Co. to enter chemical space and gain knowledge about the bioactive form, allowing the design of selective molecules.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch